Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Visa to Move European Headquarters to London’s Canary Wharf 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
